Browsing by Author "Tomasevic, R. (6603547250)"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication A NON-INVASIVE METHOD FOR ESTIMATING THE SEVERITY OF LIVER STEATOSIS AND THE RISK OF FIBROSIS IN NON-OBESE TYPE 2 DIABETES PATIENTS WITH NAFLD(2022) ;Mitrovic, B. (57211280115) ;Gluvic, Z. (24460256500) ;Klisic, A. (56160473800) ;Obradovic, Milan (48061421600) ;Macut, D. (35557111400) ;Tomasevic, R. (6603547250)Isenovic, E.R. (14040488600)Context. Prognostic considerations include assessing the risk of liver fibrosis in people with non-alcoholic fatty liver disease (NAFLD). Objectives. This study evaluates the use of hematologic and metabolic parameters regarding liver steatosis and fibrosis scores (FLI and Fib-4) in non-obese type 2 diabetes mellitus (t2DM) patients with NAFLD. Methods. Subjects underwent abdominal ultrasound examinations, and FLI and Fib-4 scores were calculated to evaluate liver steatosis and the risk of liver fibrosis non-invasively: 61 non-obese NAFLD subjects with t2DM were included in the cohort study and were divided into 2 groups depending on the t2DM treatment regimen. Results. Fib-4 and WBC count demonstrated a significant inverse correlation (OR = 0.509, p = 0.007). WBC count had an R2 of 0.237, indicating that this marker could account for up to 23.7% of a variation in Fib-4. Fib-4 and FFA had positive correlation which did not achieve statistically significant prediction (OR=7.122, p=0.062). Additionally, a significant prediction of HbA1c (OR=1.536, p=0.016) and haemoglobin (OR=1.071, p=0.020) for FLI was revealed. Conclusion. HbA1c and other haematological and metabolic parameters, such as haemoglobin and WBC, may be another non-invasive tool for determining whether non-obese NAFLD patients with t2DM are at risk of developing liver steatosis and fibrosis. © 2022, Acta Endocrinologica Foundation. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication A NON-INVASIVE METHOD FOR ESTIMATING THE SEVERITY OF LIVER STEATOSIS AND THE RISK OF FIBROSIS IN NON-OBESE TYPE 2 DIABETES PATIENTS WITH NAFLD(2022) ;Mitrovic, B. (57211280115) ;Gluvic, Z. (24460256500) ;Klisic, A. (56160473800) ;Obradovic, Milan (48061421600) ;Macut, D. (35557111400) ;Tomasevic, R. (6603547250)Isenovic, E.R. (14040488600)Context. Prognostic considerations include assessing the risk of liver fibrosis in people with non-alcoholic fatty liver disease (NAFLD). Objectives. This study evaluates the use of hematologic and metabolic parameters regarding liver steatosis and fibrosis scores (FLI and Fib-4) in non-obese type 2 diabetes mellitus (t2DM) patients with NAFLD. Methods. Subjects underwent abdominal ultrasound examinations, and FLI and Fib-4 scores were calculated to evaluate liver steatosis and the risk of liver fibrosis non-invasively: 61 non-obese NAFLD subjects with t2DM were included in the cohort study and were divided into 2 groups depending on the t2DM treatment regimen. Results. Fib-4 and WBC count demonstrated a significant inverse correlation (OR = 0.509, p = 0.007). WBC count had an R2 of 0.237, indicating that this marker could account for up to 23.7% of a variation in Fib-4. Fib-4 and FFA had positive correlation which did not achieve statistically significant prediction (OR=7.122, p=0.062). Additionally, a significant prediction of HbA1c (OR=1.536, p=0.016) and haemoglobin (OR=1.071, p=0.020) for FLI was revealed. Conclusion. HbA1c and other haematological and metabolic parameters, such as haemoglobin and WBC, may be another non-invasive tool for determining whether non-obese NAFLD patients with t2DM are at risk of developing liver steatosis and fibrosis. © 2022, Acta Endocrinologica Foundation. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication The emergence of multi-drug-resistant bacteria causing healthcare-associated infections in COVID-19 patients: a retrospective multi-centre study(2023) ;Gajic, I. (55428924700) ;Jovicevic, M. (57223044336) ;Popadic, V. (57223264452) ;Trudic, A. (56748072700) ;Kabic, J. (57215669275) ;Kekic, D. (36696225200) ;Ilic, A. (59430649200) ;Klasnja, S. (57222576460) ;Hadnadjev, M. (55362426300) ;Popadic, D.J. (58260434300) ;Andrijevic, A. (57225223464) ;Prokic, A. (58259671600) ;Tomasevic, R. (6603547250) ;Ranin, L. (6602522806) ;Todorovic, Z. (7004371236) ;Zdravkovic, M. (24924016800)Opavski, N. (6507364674)Introduction: We evaluated the prevalence, aetiologies and antibiotic resistance patterns of bacterial infections in hospitalized patients with laboratory-confirmed SARS-CoV-2. We also investigated comorbidities, risk factors and the mortality rate in COVID-19 patients with bacterial infections. Methods: This retrospective observational study evaluated medical records of 7249 randomly selected patients with COVID-19 admitted to three clinical centres between 1st January 2021 and 16th February 2022. A total of 6478 COVID-19 patients met the eligibility criteria for analysis. Results: The mean age of the patients with SARS-CoV-2 and bacterial infections was 68.6 ± 15.5 years (range: 24–94 years). The majority of patients (68.7%) were older than 65 years. The prevalence of bacterial infections among hospitalized COVID-19 patients was 12.9%, most of them being hospital-acquired (11.5%). Bloodstream (37.7%) and respiratory tract infections (25.6%) were the most common bacterial infections. Klebsiella pneumoniae and Acinetobacter baumannii caused 25.2% and 23.6% of all bacterial infections, respectively. Carbapenem-resistance in Enterobacterales, A. baumannii and Pseudomonas aeruginosa were 71.3%, 93.8% and 69.1%, respectively. Age >60 years and infections caused by ≥3 pathogens were significantly more prevalent among deceased patients compared with survivors (P<0.05). Furthermore, 95% of patients who were intubated developed ventilator-associated pneumonia. The overall in-hospital mortality rate of patients with SARS-CoV-2 and bacterial infections was 51.6%, while 91.7% of patients who required invasive mechanical ventilation died. Conclusions: Our results reveal a striking association between healthcare-associated bacterial infections as an important complication of COVID-19 and fatal outcomes. © 2023 The Authors
